» Articles » PMID: 3624248

Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin CDNA

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1987 Sep 5
PMID 3624248
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

The proper glycosylation of erythropoietin is essential for its function in vivo. Human erythropoietins were isolated from Chinese hamster ovary cells transfected with a human erythropoietin cDNA and from human urine. Carbohydrate chains attached to these proteins were isolated and fractionated by anion-exchange high performance liquid chromatography (HPLC) and HPLC employing a Lichrosorb-NH2 column. The structures of fractionated saccharides were analyzed by fast atom bombardment-mass spectrometry and methylation analysis before and after treatment with specific exoglycosidases. Both erythropoietins were found to contain one O-linked oligosaccharide/mol of the proteins, and its major component was elucidated to be NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)GalNAcOH (where NeuNAc represents N-acetylneuraminic acid) in both proteins. The N-linked saccharides of recombinant erythropoietin were found to consist of biantennary (1.4% of the total saccharides), triantennary (10%), triantennary with one N-acetyllactosaminyl repeat (3.5%), tetraantennary (31.8%), and tetraantennary with one (32.1%), two (16.5%), or three (4.7%) N-acetyllactosaminyl repeats. All of these saccharides are sialylated by 2----3-linkages. Tetraantennary with or without polylactosaminyl units are mainly present as disialosyl or trisialosyl forms, and these structures exhibit the following unique features. alpha 2----3-Linked sialic acid and N-acetyllactosaminyl repeats are selectively present in the side chains attached to C-6 and C-2 of 2,6-substituted alpha-mannose and C-4 of 2,4-substituted alpha-mannose. We have also shown that the carbohydrate moiety of urinary erythropoietin is indistinguishable from recombinant erythropoietin except for a slight difference in sialylation, providing the evidence that recombinant erythropoietin is valuable for biological as well as clinical use.

Citing Articles

Fine-tuning the N-glycosylation of recombinant human erythropoietin using Chlamydomonas reinhardtii mutants.

Leprovost S, Plasson C, Balieu J, Walet-Balieu M, Lerouge P, Bardor M Plant Biotechnol J. 2024; 22(11):3018-3027.

PMID: 38968612 PMC: 11500980. DOI: 10.1111/pbi.14424.


An etanercept O-glycovariant with enhanced potency.

Biel T, Faison T, Matthews A, Zou G, Ortega-Rodriguez U, Pegues M Mol Ther Methods Clin Dev. 2022; 25:124-135.

PMID: 35402630 PMC: 8957051. DOI: 10.1016/j.omtm.2022.03.002.


Modified recombinant human erythropoietin with potentially reduced immunogenicity.

Susantad T, Fuangthong M, Tharakaraman K, Tit-Oon P, Ruchirawat M, Sasisekharan R Sci Rep. 2021; 11(1):1491.

PMID: 33452310 PMC: 7810742. DOI: 10.1038/s41598-020-80402-1.


Large-scale site-specific mapping of the O-GalNAc glycoproteome.

Yang W, Song A, Ao M, Xu Y, Zhang H Nat Protoc. 2020; 15(8):2589-2610.

PMID: 32681153 PMC: 8620167. DOI: 10.1038/s41596-020-0345-1.


Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.

Kaltashov I, Bobst C, Pawlowski J, Wang G J Pharm Biomed Anal. 2020; 184:113169.

PMID: 32092629 PMC: 7162711. DOI: 10.1016/j.jpba.2020.113169.